Comparative Pharmacology
Head-to-head clinical analysis: BONSITY versus FOSAMAX PLUS D.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BONSITY versus FOSAMAX PLUS D.
BONSITY vs FOSAMAX PLUS D
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective estrogen receptor modulator (SERM); binds to estrogen receptors, exerting agonistic effects on bone and lipid metabolism and antagonistic effects on breast and uterine tissue.
Alendronate, a bisphosphonate, inhibits osteoclast-mediated bone resorption by binding to hydroxyapatite and interfering with the mevalonate pathway, leading to osteoclast apoptosis. Cholecalciferol (vitamin D3) promotes intestinal calcium absorption and bone mineralization.
10 mg orally once daily, taken with or without food.
One tablet (alendronate 70 mg / cholecalciferol 2800 IU) orally once weekly.
None Documented
None Documented
Terminal elimination half-life is approximately 24-30 hours; this supports once-daily dosing. Half-life may be prolonged in renal impairment.
Alendronate: Terminal half-life in bone is estimated at 10+ years due to slow release from the skeleton. Cholecalciferol: Half-life of 25-hydroxyvitamin D is ~15 days.
Renal excretion of unchanged drug accounts for 60-70% of the administered dose; biliary/fecal elimination comprises 20-25% as metabolites and unchanged drug.
Alendronate: ~50% excreted unchanged in urine; remainder is taken up by bone and slowly eliminated. No biliary or fecal excretion of intact drug. Cholecalciferol: ~50% excreted in bile via feces; less than 1% in urine.
Category C
Category C
Bisphosphonate
Bisphosphonate